GE HealthCare Unveils Allia Celeo Imaging System
The ceiling-mounted image-guided system for cardiology and interventional radiology was unveiled at a San Diego cardiovascular conference.
Updated on Nov. 2, 2026 in Heart Disease
GE HealthCare unveiled Allia Celeo, a ceiling-mounted image-guided system for cardiology and interventional radiology, on November 1 at the Transcatheter Cardiovascular Therapeutics 2026 conference in San Diego. The system is CE marked and pending clearance with the U.S. Food and Drug Administration, and is not yet available for sale in the United States.
Why it matters
Allia Celeo is the second Allia system introduced in less than a year, following the floor-mounted Allia Moveo, signaling continued investment in image-guided procedure platforms. Its U.S. availability will depend on the pending FDA clearance.
The unveiling is a manufacturer product announcement rather than clinical evidence, with the system's features including an extra-wide-bore C-arm, AI-enabled image chain, and integration with StentViz, Valve Assist 2, Embo Assist AI, and the Mac-Lab hemodynamic system. Performance outcomes and U.S. regulatory status remain unresolved, as the system is pending FDA clearance and not yet available for sale in the United States.
The players
GE HealthCare
GE HealthCare is a major global medical technology company that develops diagnostic imaging, ultrasound, and patient care solutions used in hospitals worldwide.
The details
Allia Celeo features an extra-wide-bore C-arm on a ceiling gantry with integrated cabling, designed to reach steep angulations including in patients with a high body mass index. Its AI-enabled image chain automatically adjusts acquisition parameters to balance image quality and radiation dose across 2D and 3D imaging, and an on-screen digital twin assists with gantry and table positioning.
Timeline
November 1, 2026: GE HealthCare unveils Allia Celeo at the Transcatheter Cardiovascular Therapeutics 2026 conference in San Diego.
Roadmap
Allia Celeo follows the floor-mounted Allia Moveo, which GE HealthCare introduced less than a year earlier, forming a second Allia platform in that span. The ceiling-mounted design extends the line's approach to cardiology and interventional radiology suites, where image-guided catheter procedures are increasingly performed.
Hospitals and cardiac labs in the United States cannot yet purchase Allia Celeo until the FDA grants clearance. Patients undergoing catheter-based cardiac and vascular procedures would only be affected once facilities adopt the system.
The takeaway
Imaging platforms for catheter-based heart procedures are advancing quickly, but U.S. availability depends on regulatory clearance. Readers interested in heart procedure technology can track FDA decisions on new cardiac imaging systems.
Further reading
Explore more on Heart Disease and how image-guided technology is changing cardiac procedures.
